Physician profile
Jackson Norris
NPI 1174205876
$1,537.11
in general payments reported to CMS, 2019-2025
16 companies · $856 in 2025
The $856 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $128 · 2024: $553 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.59 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $273.12 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $205.79 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $175.20 | 2024-2025 | Ingrezza |
| Abbvie INC. | $158.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $155.63 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $120.81 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $102.47 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $89.79 | 2023-2025 | Austedo Xr, Uzedy |
| Lilly USA, LLC | $57.32 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $51.06 | 2024-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.49 | 2024-2025 | Caplyta |
| Lundbeck LLC | $31.85 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.33 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $16.77 | 2024 | Qelbree |
| Exact Sciences Corporation | $16.69 | 2025 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.